Hansoh Pharmaceutical Group Company Limited

Price Chart

Risk-Adjusted Performance

Hansoh Pharmaceutical Group Company Limited (HNSPF) Price Performance

Hansoh Pharmaceutical Group Company Limited (HNSPF) trades on United States in USD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at $5.16.

Over the past year, HNSPF has traded between a low of $2.28 and a high of $5.17. The stock has gained 93.9% over this period. It is currently 126.8% above its 52-week low.

Hansoh Pharmaceutical Group Company Limited has a market capitalization of $32.81B, with a price-to-earnings ratio of 43.00 and a dividend yield of 6.59%.

About Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.